• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

    7/10/23 10:41:25 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ICPT alert in real time by email
    SC 13G/A 1 tv0002-interceptpharmaceutic.htm SCHEDULE 13G/A interceptpharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  Intercept Pharmaceuticals Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  45845P108

    Date of Event Which Requires Filing of this Statement: June 30, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  45845P108

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    46,592

    7.  SOLE DISPOSITIVE POWER

    4,616,408

    8.  SHARED DISPOSITIVE POWER

    77,399

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,693,807

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.26%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Intercept Pharmaceuticals Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    305 Madison Avenue
    Morristown, NJ 07960

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    45845P108

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  July 10, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ICPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICPT

    DatePrice TargetRatingAnalyst
    7/13/2023$8.00 → $19.00Sell → Buy
    H.C. Wainwright
    6/29/2023$12.00 → $18.00Hold → Buy
    Canaccord Genuity
    5/23/2023Buy → Hold
    Needham
    5/22/2023$8.00Neutral → Sell
    H.C. Wainwright
    5/17/2023Outperform → Mkt Perform
    Raymond James
    3/8/2022$31.00 → $29.00Hold
    Canaccord Genuity
    3/3/2022$22.00 → $16.00Sector Perform
    RBC Capital
    3/3/2022$30.00 → $25.00Buy
    Needham
    More analyst ratings

    $ICPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

      -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

      10/23/23 8:00:00 AM ET
      $CSTL
      $EQ
      $ICPT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer

      NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer. “Dr. Berrey brings a wealth of leadership experience in drug development and executive management to Intercept, and I am very pleased to welcome her to the team,” said Jerry Durso, President and Chief Executive Officer of Intercept. “She joins us at a pivotal time for the company as we continue to drive our foundational PB

      6/9/21 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors

      NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021. Ms. Rosa-Bjorkeson has more than 25 years of global experience in the pharmaceutical industry, including executive leadership positions in corporate and product strategy, market development and operational execution. She is currently the Chief Operating Officer of Mesoblast Limited. Ms. Rosa-Bjorkeson has led multiple successful product launches, inclu

      2/23/21 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Intercept Pharma upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Intercept Pharma from Sell to Buy and set a new price target of $19.00 from $8.00 previously

      7/13/23 9:10:56 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Pharma upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Intercept Pharma from Hold to Buy and set a new price target of $18.00 from $12.00 previously

      6/29/23 7:24:17 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Pharma downgraded by Needham

      Needham downgraded Intercept Pharma from Buy to Hold

      5/23/23 7:40:07 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      2/25/22 4:36:46 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      5/27/21 5:23:24 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference

      MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C. "We are pleased to participate in this year's DDW and share our latest findings, including new data from our Phase 2 trial evaluating a fixed-dose combination of obeticholic acid and bezafibrate in patients with PBC," said Sangeeta Sawh

      5/9/24 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

      sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registriesFDA has assigned a PDUFA target action date of October 15, 2024 MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supple

      2/29/24 8:30:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

      BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. ("Alfasigma") and Intercept Pharmaceuticals, Inc. ("Intercept") announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma's successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes, Alfasigma acquired all remaining shares of common stock of Intercept through a merger pursuant to Section 251(h) of the General Corporation Law of the St

      11/8/23 9:13:49 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Intercept Pharmaceuticals Inc.

      15-12G - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)

      11/20/23 12:09:56 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.

      EFFECT - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)

      11/15/23 12:15:07 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.

      EFFECT - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Filer)

      11/15/23 12:15:03 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Akkaraju Srinivas returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)

      4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)

      11/13/23 2:51:46 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fundaro Paolo returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)

      4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)

      11/13/23 2:47:18 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Venezia Rocco returned $278,711 worth of shares to the company (14,669 units at $19.00), closing all direct ownership in the company (SEC Form 4)

      4 - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Issuer)

      11/13/23 2:49:33 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Subject)

      10/10/23 11:07:16 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Subject)

      7/10/23 10:41:25 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INTERCEPT PHARMACEUTICALS, INC. (0001270073) (Subject)

      2/14/23 4:01:07 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Financials

    Live finance-specific insights

    See more
    • Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

      MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET. Participants can access the conference call live via webcast which will be available on the investor page of the company's website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the

      7/26/23 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

      Company to discontinue all NASH-related investment and restructure the Company's operations to strengthen its focus on rare and serious liver diseasesCompany anticipates achieving profitability in 2024 as a result of planned actionsConference call scheduled for Friday, June 23, 2023, at 8:30 a.m. ET MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company's New Drug Applicat

      6/22/23 5:45:00 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

      12 of 16 voting-eligible advisors vote "no" (with two abstentions) on question, "given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with stage 2 or 3 fibrosis?" 15 of 16 voting-eligible advisors vote to "defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional approval pathway could be considered" PDUFA Target Action Date set for June 22, 2023 Company to host conference call on Monday, May 22, 2023, at 8:30 a.m. ET MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development

      5/19/23 6:45:00 PM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care